Abstract
The advancing edge profile is a powerful determinant of tumor behavior in many organs. In this study, a grading system assessing the tumor-host interface was developed and tested in 181 pancreatic neuroendocrine tumors (PanNETs), 63 of which were <=2 cm. Three tumor slides representative of the spectrum (least, medium, and most) of invasiveness at the advancing edge of the tumor were selected, and then each slide was scored as follows. Well-demarcated/encapsulated, 1 point; Mildly irregular borders and/or minimal infiltration into adjacent tissue, 2 points; Infiltrative edges with several clusters beyond the main tumor but still relatively close, and/or satellite demarcated nodules, 3 points; No demarcation, several cellular clusters away from the tumor, 4 points; Exuberantly infiltrative pattern, scirrhous growth, dissecting the normal parenchymal elements, 5 points. The sum of the rankings on the three slides was obtained. Cases with scores of 3–6 were defined as “non/minimally infiltrative” (NI; n = 77), 7–9 as “moderately infiltrative” (MI; n = 68), and 10–15 as “highly infiltrative” (HI; n = 36). In addition to showing a statistically significant correlation with all the established signs of aggressiveness (grade, size, T-stage), this grading system was found to be the most significant predictor of adverse outcomes (metastasis, progression, and death) on multivariate analysis, more strongly than T-stage, while Ki-67 index did not stand the multivariate test. As importantly, cases <=2 cm were also stratified by this grading system rendering it applicable also to this group that is currently placed in “watchful waiting” protocols. In conclusion, the proposed grading system has a strong, independent prognostic value and therefore should be considered for integration into routine pathology practice after being evaluated in validation studies with larger series.
Your institute does not have access to this article
Relevant articles
Open Access articles citing this article.
-
“Pure” hepatoid tumors of the pancreas harboring CTNNB1 somatic mutations: a new entity among solid pseudopapillary neoplasms
Virchows Archiv Open Access 31 March 2022
Access options
Subscribe to Journal
Get full journal access for 1 year
We are sorry, but there is no personal subscription option available for your country.
Buy article
Get time limited or full article access on ReadCube.
$32.00
All prices are NET prices.








Data availability
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
References
Li, C., Xiang, J. & Wang, Y. Risk factors for predicting lymph nodes posterior to right recurrent laryngeal nerve (Ln-PRRLN) metastasis in thyroid papillary carcinoma: a meta-analysis. Int. J. Endocrinol. 2019, 7064328 (2019).
Jung, C. K. et al. Unique patterns of tumor growth related with the risk of lymph node metastasis in papillary thyroid carcinoma. Mod. Pathol. 23, 1201–1208 (2010).
Taşkın, O. et al. Tumor border pattern and size help predict lymph node status in papillary microcarcinoma: a clinicopathologic study. Ann. Diagn. Pathol. 48, 151592 (2020).
Lloyd, R., Osamura, R., Klöppel, G. & Rosai, J. WHO classification of tumours of the endocrine organs, 4th edn. (International Agency for Research on Cancer, 2017).
Gulluoglu, M. et al. Tumor budding is independently predictive for lymph node involvement in early gastric cancer. Int. J. Surg. Pathol. 23, 349–358 (2015).
Ohike, N. et al. Tumor budding as a strong prognostic indicator in invasive ampullary Adenocarcinomas. Am. J. Surg. Pathol. 34, 1417–1424 (2010).
Ito, T. et al. High tumor budding is a strong predictor of poor prognosis in the resected perihilar cholangiocarcinoma patients regardless of neoadjuvant therapy, showing survival similar to those without resection. BMC Cancer https://doi.org/10.1186/s12885-020-6695-9 (2020).
Lugli, A. et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod. Pathol. 30, 1299–1311 (2017).
Lawlor, R. T. et al. Prognostic role of high-grade tumor budding in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis with a focus on epithelial to mesenchymal transition. Cancers (Basel) 11, 113 https://doi.org/10.3390/cancers11010113 (2019).
Losi, L. et al. Prognostic significance of histological features and biological parameters in stage I (pT1 and pT2) colorectal adenocarcinoma. Pathol. Res. Pract. 202, 663–670 (2006).
Shih, A. R. & Mino‐Kenudson, M. Updates on spread through air spaces (STAS) in lung cancer. Histopathology 77, 173–180 (2020).
Amin, M. B. et al. AJCC Cancer Staging Manual, 8th edn. (Springer International Publishing, American Joint Commission on Cancer, 2017).
Japan Pancreas Society. in Classification of Pancreatic Carcinoma, 4th English Edn., 70–101 (Kanehara & Co., Ltd, 2017).
Zhang, L. et al. KIT is an independent prognostic marker for pancreatic endocrine tumors: a finding derived from analysis of islet cell differentiation markers. Am. J. Surg. Pathol. 33, 1562–1569 (2009).
Chatterjee, D. et al. Intratumoral fibrosis and tumor growth pattern as prognostic factors in optimally resected pancreatic neuroendocrine neoplasms: an analysis of 168 cases. Pancreas 49, 255–260 (2020).
Shi, H., Zhang, Q., Han, C., Zhen, D. & Lin, R. Variability of the Ki-67 proliferation index in gastroenteropancreatic neuroendocrine neoplasms—a single-center retrospective study. BMC Endocr. Disord. 18, 51 https://doi.org/10.1186/s12902-018-0274-y (2018).
Nuñez‐Valdovinos, B. et al. Neuroendocrine tumor heterogeneity adds uncertainty to the World Health Organization 2010 Classification: real‐world data from the Spanish Tumor Registry (R‐GETNE). Oncologist 23, 422–432 (2018).
Liszka, Ł. Tissue heterogeneity contributes to suboptimal precision of WHO 2010 scoring criteria for Ki67 labeling index in a subset of neuroendocrine neoplasms of the pancreas. Pol. J. Pathol. 67, 318–331 (2016).
Pea, A. et al. Genetic analysis of small well-differentiated pancreatic neuroendocrine tumors identifies subgroups with differing risks of liver metastases. Ann. Surg. 271, 566–573 (2020).
Koelzer, V. H. & Lugli, A. The tumor border configuration of colorectal cancer as a histomorphological prognostic indicator. Front. Oncol. 4, 29 (2014).
Karamitopoulou, E. et al. Tumour border configuration in colorectal cancer: proposal for an alternative scoring system based on the percentage of infiltrating margin. Histopathology 67, 464–473 (2015).
Xue, Y. et al. Growth pattern of invasive ampullary carcinomas as demarcated versus infitlrative has significant prognostic correlation: a clinicopathologic analysis of 257 cases. United States & Canadian Academy of Pathology Annual Meeting Abstracts. Mod. Pathol. 31, 313 (2018).
Reid, M. D. et al. Calculation of the Ki67 index in pancreatic neuroendocrine tumors: a comparative analysis of four counting methodologies. Mod. Pathol. 28, 686–694 (2015).
Gaujoux, S. et al. Observational study of natural history of small sporadic nonfunctioning pancreatic neuroendocrine tumors. J. Clin. Endocrinol. Metab. 98, 4784–4789 (2013).
Pavlakis, K. et al. MELF invasion in endometrial cancer as a risk factor for lymph node metastasis. Histopathology 58, 966–973 (2011).
Mccall, C. M. et al. Serotonin expression in pancreatic neuroendocrine tumors correlates with a trabecular histologic pattern and large duct involvement. Hum. Pathol. 43, 1169–1176 (2012).
Chou, A. et al. ATRX loss is an independent predictor of poor survival in pancreatic neuroendocrine tumors. Hum. Pathol. 82, 249–257 (2018).
Roy, S. et al. Loss of chromatin-remodeling proteins and/or CDKN2A associates with metastasis of pancreatic neuroendocrine tumors and reduced patient survival times. Gastroenterology 154, 2060–2063.e8 (2018).
Hackeng, W. M. et al. Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size. Gut https://doi.org/10.1136/gutjnl-2020-322595 (2021).
Jiao, Y. et al. DAXX/ATRX, MEN1 and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331, 1199–1203 (2011).
Ishida, H. & Lam, A. K. Y. Pancreatic neuroendocrine neoplasms: the latest surgical and medical treatment strategies based on the current World Health Organization classification. Crit. Rev. Oncol. Hematol. 145, 102835 https://doi.org/10.1016/j.critrevonc.2019.102835 (2020).
Lopez-Aguiar, A. G. et al. The conundrum of <2-cm pancreatic neuroendocrine tumors: a preoperative risk score to predict lymph node metastases and guide surgical management. Surgery 166, 15–21 (2019).
Melia, J. et al. A UK-based investigation of inter- and intra-observer reproducibility of Gleason grading of prostatic biopsies. Histopathology 48, 644–654 (2006).
Montironi, R. et al. Gleason grading of prostate cancer in needle biopsies or radical prostatectomy specimens: Contemporary approach, current clinical significance and sources of pathology discrepancies. BJU Int. 95, 1146–1152 (2005).
Rabe, K. et al. Interobserver variability in breast carcinoma grading results in prognostic stage differences. Hum. Pathol. 94, 51–57 (2019).
Meyer, J. S. et al. Breast carcinoma malignancy grading by Bloom-Richardson system vs proliferation index: Reproducibility of grade and advantages of proliferation index. Mod. Pathol. 18, 1067–1078 (2005).
Mahajan, D. et al. Reproducibility of the villous component and high-grade dysplasia in colorectal adenomas <1 cm: Implications for endoscopic surveillance. Am. J. Surg. Pathol. 37, 427–433 (2013).
Vennalaganti, P. et al. Discordance among pathologists in the United States and Europe in diagnosis of low-grade dysplasia for patients with Barrett’s esophagus. Gastroenterology 152, 564–570.e4 (2017).
Downs-Kelly, E. et al. Poor interobserver agreement in the distinction of high-grade dysplasia and adenocarcinoma in pretreatment Barrett’s esophagus biopsies. Am. J. Gastroenterol. 103, 2333–2340 (2008).
Kerkhof, M. et al. Grading of dysplasia in Barrett’s oesophagus: substantial interobserver variation between general and gastrointestinal pathologists. Histopathology 50, 920–927 (2007).
Dano, H. et al. Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion study. Mod. Pathol. 33, 354–366 (2020).
Acknowledgements
This study was presented in part at the 110th annual meeting of the United States and Canadian Academy of Pathology in March 2021.
Funding
The authors received no specific funding for this work.
Author information
Authors and Affiliations
Contributions
V. A., A. S., C. L., and O. B. conceptualized and designed the study; V. A., P. B., M. D. R., and C. S. devised the scoring protocol. M. D. R., P. B., B. P., Y. X., O. C. T., A. A., C. S., and V. A. identified the patients; D. D., A. B., E. B., A. B., B. M., C. B. L, B. P., and Y. X. compiled and organized the data; O. C. T., M. D. R., P. B., B. S., Y. X., Y. K., C. S., and V. A. reviewed histopathology. S.B. and A.B. performed statistical analyses. S. B., O. C. T, O. B., and V. A. analyzed data. O. C. T., M. D. R., B. P., O. B., and V. A. wrote the manuscript. D. D, E. B., B. P., and O. C. T. organized the figures and the tables. All the authors critically read, edited, and approved the final manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethics approval
This study was performed in accordance with the Declaration of Helsinki.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Taskin, O.C., Reid, M.D., Bagci, P. et al. Infiltration pattern predicts metastasis and progression better than the T-stage and grade in pancreatic neuroendocrine tumors: a proposal for a novel infiltration-based morphologic grading. Mod Pathol 35, 777–785 (2022). https://doi.org/10.1038/s41379-021-00995-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41379-021-00995-4